Future studies with broader exploratory genomic sequencing efforts are warranted to determine if co-mutations affect the clinical activity of ivosidenib for mIDH1 advanced conventional CS (i.e., it is not known if additional cumulative mutations in cancer drivers or tumor suppressors may overcome any IDH1-directed antitumor activity). Here, IDH1 is linked to neoplasm.